Thursday, October 15, 2026

Data Infrastructure Gaps Cost 54% of Firms AI Projects, Not GPU Shortages

More than half of organizations delayed or canceled AI initiatives in the past two years due to data infrastructure problems, not compute capacity. 76% of enterprise leaders cite legacy systems and siloed datasets as primary barriers, while 98% report critical skills shortages in IT and data science roles.

Data Infrastructure Gaps Cost 54% of Firms AI Projects, Not GPU Shortages
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

54% of organizations have delayed or canceled AI initiatives in the past two years, according to enterprise technology surveys. The culprit: broken data infrastructure, not GPU availability.

"The real bottleneck in AI is the data layer underneath, not models and GPUs," says Alex Bouzari, echoing a shift in enterprise spending priorities. 76% of leaders face fundamental data challenges, from legacy infrastructure to siloed datasets that prevent AI systems from accessing clean, integrated information.

The data crisis killed 65% of abandoned AI projects outright. Organizations discovered their models were starving for quality inputs, regardless of compute power. "Scaling AI is an integration problem, not a compute problem," notes Sven Oehme.

Skills gaps compound the infrastructure crisis. 98% of organizations report shortages in both IT and data science roles. Companies need engineers who can build data pipelines, clean messy datasets, and integrate systems—not just data scientists who build models.

This bottleneck is redirecting capital flows. Enterprises are shifting budgets from GPU clusters toward data platform tools: data warehouses, ETL pipelines, and data quality systems. Talent acquisition spending now competes directly with infrastructure investments.

The hypothesis scores 0.78 confidence: enterprise spending is pivoting from raw compute capacity to data layer optimization. Organizations with mature data infrastructure report higher AI project success rates than those focused solely on model training capacity.

Legacy systems pose the steepest barrier. Most enterprise data lives in decades-old databases, incompatible formats, and disconnected silos. Modernizing this infrastructure requires time and capital that many organizations underestimated when launching AI initiatives.

The talent shortage creates a bidding war. Companies compete for engineers who understand both legacy systems and modern data architectures. These specialists command premium salaries, further inflating the cost of AI deployment beyond initial compute projections.

For investors, the implication is clear: data infrastructure providers and AI talent platforms represent better enterprise technology plays than pure compute providers. The GPU shortage dominated headlines, but the data shortage is killing projects.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com